GSK plc has revealed promising interim results from its AZUR-1 trial, which evaluates the efficacy of its drug Jemperli (dostarlimab) in treating patients with locally advanced rectal cancer. The trial findings indicate that 76% of evaluable patients achieved a complete response to the treatment, a significant milestone that could change how this cancer is managed.
The AZUR-1 trial specifically focused on adults with stage II and III microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) rectal cancer. The results are particularly noteworthy as they suggest that a substantial proportion of patients may avoid traditional treatments like chemotherapy, radiation, and surgery, which often come with severe side effects.
Background
GSK plc, incorporated in the UK, operates in the pharmaceutical preparations sector (SIC 2834). The company trades under the tickers GSK and GLAXF on the NYSE and OTC exchanges, respectively. Recent filings from GSK include multiple 6-K forms, with the latest dated October 26, 2026, detailing the AZUR-1 trial results.
What the Filing Says
The filing states, "76% of evaluable patients (110/144) achieved a complete response to dostarlimab alone." It further notes that no disease recurrences have been reported among responders after a median follow-up of over two years, emphasizing the potential of Jemperli as a transformative treatment.
Impact
The results from the AZUR-1 trial may significantly affect patients diagnosed with locally advanced rectal cancer, offering them a new treatment option that could spare them from the harsh side effects associated with conventional therapies. Additionally, these findings could influence healthcare providers and oncologists, prompting them to reconsider treatment protocols for this patient population.
What's Next
The filing does not say what happens next, but the positive results are expected to be presented at the European Society for Medical Oncology (ESMO) Congress, furthering GSK's visibility in the oncology sector.
GSK develops differentiated medicines for cancers where advances in science and technology offer the greatest opportunity to improve patient outcomes.